Skip to main content
Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time
Alerts Watchlist Portfolio

Today's Trading

Day Low 81.29
Day High 82.74
Open:81.97
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
u.s. business
Merck sells stake in vaccine developer Moderna
Subscriber content
inside the market
Market movers: Stocks that saw action on Wednesday - and why
Subscriber content
inside the market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
investment ideas
Berkshire’s bet a bright spot in gloomy year for Big Pharma stocks
inside the market
Market movers: Stocks that saw action on Tuesday - and why
Subscriber content
international business
Warren Buffett’s Berkshire Hathaway invests in four big drugmakers, cuts stake in Barrick
Subscriber content
Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
- PR Newswire - PRF - Wed Dec 2, 8:30AM CST
PR Newswire - PRF - CMTX
Wed Dec 2, 8:30AM CST
, /PRNewswire/ --   - Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and  Unlike other breast cancers, treatments for TNBC involving  With a dire need for new forms of treatment, there's plenty of optimism surrounding the efforts of pharma developers towards TNBC, including the work of (NASDAQ: ONCY) (TSX: ONC), (NASDAQ: INCY), (OTC: RHHBY), (NYSE: MRK) and . (OTCQB: CYDY).
Tarus Therapeutics Strengthens its Board of Directors with Appointment of Paolo Pucci
- ACCESSWIRE - Wed Dec 2, 6:00AM CST
ACCESSWIRE - CMTX
Wed Dec 2, 6:00AM CST
NEW YORK, NY / ACCESSWIRE / December 2, 2020 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointment of Paolo Pucci as a new Board Director.
SmarTrend Watching for Potential Pullback in Shares of Merck & Co After 1.49% Gain
- Comtex SmarTrend(R) - Tue Dec 1, 10:59AM CST
Comtex SmarTrend(R) - CMTX
Tue Dec 1, 10:59AM CST
Merck & Co (NYSE:MRK) traded in a range yesterday that spanned from a low of $80.84 to a high of $82.46. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $80.68 on volume of 4.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 76.76 +6.61% increase
on 11/03/20
Period Open:76.71
Price movement based on the high, low and last over the given period.
85.17 -3.92% decrease
on 11/09/20
 +5.12 (+6.67%) increase
since 11/02/20
3-Month 73.94 +10.67% increase
on 10/30/20
Period Open:86.93
Price movement based on the high, low and last over the given period.
87.80 -6.80% decrease
on 09/03/20
 -5.10 (-5.87%) decrease
since 09/02/20
52-Week 65.25 +25.41% increase
on 03/23/20
Period Open:87.04
Price movement based on the high, low and last over the given period.
92.64 -11.67% decrease
on 12/20/19
 -5.21 (-5.99%) decrease
since 12/02/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies